HUMA (Humacyte) Total Operating Expense: $104.31 Mil (TTM As of Mar. 2026)


HUMA Humacyte Inc HUMA
23 GF Score
Price $0.71
! 6 Warning Signs
View Full Analysis

What is Humacyte Total Operating Expense?

Humacyte HUMA -0.90% 23 Total Operating Expense is $104.31 Mil as of Mar. 2026. GuruFocus rates HUMA with a GF Score™ of 23/100. The stock has 6 warning signs investors should review.

Humacyte's Total Operating Expense for the three months ended in Mar. 2026 was $27.39 Mil. Humacyte's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $104.31 Mil.

Humacyte Total Operating Expense Related Terms

Humacyte Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Humacyte's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Humacyte Total Operating Expense Chart

Humacyte Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 81.21 84.58 100.05 114.40 100.47

Humacyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.55 29.82 24.88 22.22 27.39
HUMA
23GF Score
Humacyte Inc HUMA
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Humacyte Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $104.31 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $104.31 Mil mean?
Humacyte (HUMA) has a Total Operating Expense of $104.31 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Humacyte and its competitors.
Is Humacyte's Total Operating Expense too high?
Humacyte's current Total Operating Expense is $104.31 Mil. Overall, Humacyte has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Humacyte's Total Operating Expense compare to ORMP and EQ?
Humacyte's Total Operating Expense of $104.31 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Humacyte and its competitors. Humacyte's current Total Operating Expense is $104.31 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humacyte stock overvalued right now?
Humacyte (HUMA) has a current Total Operating Expense of $104.31 Mil. The current Total Operating Expense is $104.31 Mil. Humacyte's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Humacyte (HUMA), the current Total Operating Expense is $104.31 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Humacyte Business Description

Address 2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a commercial-stage biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
23GF Score

Get the complete analysis for HUMA

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price